FY2025 EPS Estimates for AbbVie Raised by Cantor Fitzgerald

AbbVie Inc. (NYSE:ABBV) – Research analysts at Cantor Fitzgerald lifted their FY2025 EPS estimates for AbbVie in a research note issued on Wednesday, August 13th. Cantor Fitzgerald analyst C. Gould now anticipates that the company will post earnings of $12.05 per share for the year, up from their previous forecast of $11.84. Cantor Fitzgerald has a “Overweight” rating and a $210.00 price objective on the stock. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share. Cantor Fitzgerald also issued estimates for AbbVie’s FY2026 earnings at $14.35 EPS.

Other equities research analysts have also issued reports about the stock. Raymond James Financial lifted their price target on shares of AbbVie from $227.00 to $236.00 and gave the company an “outperform” rating in a report on Friday, August 1st. Citigroup boosted their target price on shares of AbbVie to $205.00 and gave the stock a “hold” rating in a research note on Wednesday, June 11th. Evercore ISI increased their price target on AbbVie from $204.00 to $205.00 and gave the company an “outperform” rating in a research note on Monday, April 28th. Bank of America raised their price objective on AbbVie to $204.00 and gave the company a “hold” rating in a report on Monday, June 9th. Finally, Morgan Stanley upped their target price on AbbVie from $250.00 to $255.00 and gave the stock an “overweight” rating in a report on Friday, August 1st. Six investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and five have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $214.95.

AbbVie Stock Up 1.0%

Shares of NYSE ABBV opened at $206.65 on Friday. The company has a market cap of $365.06 billion, a price-to-earnings ratio of 98.41, a PEG ratio of 1.33 and a beta of 0.50. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14. AbbVie has a 12 month low of $163.81 and a 12 month high of $218.66. The stock has a 50-day moving average price of $191.08 and a two-hundred day moving average price of $192.20.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Thursday, July 31st. The company reported $2.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.24 by ($0.27). AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The business had revenue of $15.42 billion during the quarter, compared to the consensus estimate of $14.93 billion. During the same quarter in the previous year, the business posted $2.65 EPS. The company’s revenue for the quarter was up 6.6% on a year-over-year basis.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ABBV. Marshall & Sullivan Inc. WA bought a new stake in shares of AbbVie in the 2nd quarter worth $25,000. TD Capital Management LLC boosted its holdings in AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after purchasing an additional 58 shares during the last quarter. Spurstone Advisory Services LLC bought a new stake in AbbVie in the 2nd quarter worth about $28,000. Abound Financial LLC purchased a new stake in AbbVie in the 1st quarter valued at about $30,000. Finally, Siemens Fonds Invest GmbH increased its stake in AbbVie by 197.6% in the 4th quarter. Siemens Fonds Invest GmbH now owns 179,440 shares of the company’s stock valued at $32,000 after buying an additional 119,141 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insider Transactions at AbbVie

In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the transaction, the executive vice president owned 177,292 shares in the company, valued at $35,178,278.64. The trade was a 19.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Nicholas Donoghoe sold 13,295 shares of the stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $198.51, for a total transaction of $2,639,190.45. Following the transaction, the executive vice president directly owned 58,247 shares in the company, valued at approximately $11,562,611.97. This represents a 18.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.25% of the company’s stock.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th were issued a dividend of $1.64 per share. This represents a $6.56 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date was Tuesday, July 15th. AbbVie’s dividend payout ratio (DPR) is presently 312.38%.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.